Global Chemiluminescence Immunoassay Market Analysis, 2020-2027 – Focus on Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Chemiluminescence Immunoassay Market Share, Size, Trends, Industry Analysis Report, By Product; By Application; By End Use; By Regions; Segment Forecast, 2020-2027” report has been added to ResearchAndMarkets.com’s offering.
The global chemiluminescence immunoassay market is expected to reach USD 10.67 billion by 2027.
The global chemiluminescence immunoassay market is driven by few notable factors such as rapid surge in the COVID-19 cases, the awareness among the people about timely medical attention, and rapidly improving healthcare infrastructure in terms of rapid testing, which in turn, boosting the chemiluminescence immunoassay industry growth. Chemiluminescence immunoassay solutions are also used for detection of numerous severe diseases including autoimmune disease, cancer, and diabetes, among others.
The global chemiluminescence immunoassay industry is segmented on the basis of product, application, end-use, and region. In terms of product, the market is segmented into instruments, consumables, and software and services. Based on application, the market is classified as therapeutic drug monitoring, oncology, cardiology, endocrinology, infectious disease, autoimmune disease, and others. The end-use segment is further divided into hospitals, clinical laboratories, pharmaceutical & biotechnology companies, and others.
Segment Highlights
- The consumables segment of chemiluminescence immunoassay industry accounted for the largest revenue share in 2019 and is expected to continue its dominance over the forecast period. This can be attributed to the increasing demand for stains or reagents in therapeutics such as endocrinology and drug monitoring.
- Based on application, the infectious diseases segment is projected to constitute almost half of the market by the end of 2027 on account of the aggressive use of chemiluminescence immunoassay solutions in the healthcare industry to check pandemic infection in across the regions.
- Hospitals segment is expected to account for the largest revenue share by the end of 2027 on account of the increasing footfall in hospitals for the treatment of several infectious diseases and chronic diseases such as cancer driving chemiluminescence immunoassay solutions.
List of Key Players
- DiaSorin S.p.A.
- F. Hoffmann-La Roche AG
- Abbott Laboratories
- Immunodiagnostic Systems
- Maccura Biotechnology Co. Ltd.
- Shenzhen Mindray
- Beckman Coulter Inc.
- Siemens Healthineers
- Inova Diagnostics Inc.
- Ortho Clinical Diagnostics
For more information about this report visit https://www.researchandmarkets.com/r/ue8l6v
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
